Close

BIO Applauds House Passage of the 21st Century Cures Act

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO Responds to GAO Report Declaring RFS Will Not Meet Goals

BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels but we would observe that EPA has chilled investment in commercializing this technology.

BIO Welcomes EPA’s Final 2017 Renewable Fuel Standards

The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and cellulosic biofuels.

DSCSA: BIO Submits Comments to FDA's Public Meeting on Progress Toward Implementing the Product Identification Requirements of the Drug Supply Chain Security Act

Re: Docket No. FDA–2016–N–2673: Public Meeting on Progress Toward Implementing the Product Identification Requirements of the Drug Supply Chain Security Act ...

BIO Position on Proposals to Provide for Export Manufacturing Exemption during Patent Term Restoration

Export manufacturing exemptions weaken the IP protections afforded by Supplementary Protection Certificate and Patent Term Restoration.

BIO Statement on FDA Product Communications Hearing

BIO President and CEO Jim Greenwood released the following statement today regarding the FDA’s hearing on product communications: “In the era of data-driven medicine, where all parties seek more, not less, information about the safety, effectiveness, and value of treatments, fostering informed communications among all stakeholders is critical.  We are in the midst of a transition to value-based healthcare – a transition that has the potential to improve the efficiency of the overall healthcare system. Earlier this year, BIO and its members endorsed a systemic set of principles and commitments in support of moving us toward a value-based system – the first major healthcare industry association to do so.  

BIO Patient and Health Advocacy Summit Hosts Over 300 Attendees from Wide Range of Health Care Organizations

Over 200 diverse groups were represented at the November 3-4 meeting in Washington, D.C.

BIO Submits Comments in Reponse to the Notice of a Request for Information re Clarifying Current Roles and Responsibilities Described in the Coordinated Framework for the Regulation of Biotechnology

BIO is pleased to submit these comments in response to the Notice of Request for Public Comment published by the National Science and Technology Council, Science and Technology Policy Office. The Coordinated Framework for Regulation of Biotechnology (Coordinated Framework) has made it possible for BIO members to develop products that have improved the productivity of plant and animal agriculture while decreasing their environmental impacts, enhanced food safety and quality, increased the use of renewable resources and decreased manufacturing costs and energy use.

BIO Issues Call for Papers for 2017 World Congress on Industrial Biotechnology in Montréal

BIO has officially issued a call to leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors industries to submit panel session proposals for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada.

BIO submits amicus brief In Re Aqua Products, Inc. (U.S. Court of Appeals for the Federal Circuit)

The Biotechnology Innovation Organization submitted a brief of amicus curiae supporting the appellant in the case In Re: Aqua Product, Inc. in the United States Court of Appeals for the Federal Circuit